Ronit Gurion
YOU?
Author Swipe
View article: ICE therapy for primary and secondary central nervous system involvement of lymphomas
ICE therapy for primary and secondary central nervous system involvement of lymphomas Open
Central nervous system (CNS) lymphomas, including primary CNS lymphoma (PCNSL) and secondary CNS lymphoma (sCNSL), are aggressive and challenging diseases with dismal outcomes. Due to its CNS-penetrating properties, ifosfamide, carboplatin…
View article: Characterization of persistent COVID-19: An emerging post- pandemic crisis in immunocompromised patients. An observational cohort study
Characterization of persistent COVID-19: An emerging post- pandemic crisis in immunocompromised patients. An observational cohort study Open
Introduction Persistent coronavirus disease 2019 (pCOVID-19) is an emerging complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, particularly among immunocompromised patients. We aimed to characterize our…
View article: The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma Open
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome that complicates hematologic malignancies. The Optimized HLH Inflammatory (OHI) index, based solely on the combined elevation of soluble CD25 (sCD25; >3900 U/mL) a…
View article: Tumor‐Associated Lactic Acidosis and Early Death in Patients With Lymphoma
Tumor‐Associated Lactic Acidosis and Early Death in Patients With Lymphoma Open
Background Cancer is characterized by accelerated glycolysis with enhanced glucose uptake and lactate production, a phenomenon termed Warburg effect (WE). We studied the incidence and clinical impact of Warburg‐driven lactic acidosis in ly…
View article: Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma Open
Therapy for relapsed or refractory (R/R) aggressive B‐cell non‐Hodgkin lymphoma (aB‐NHL) post autologous stem cell transplantation (ASCT) or in elderly patients can be challenging. In this single‐center, single‐arm, phase II clinical study…
View article: A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204) Open
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell lymphomas. The phase 2 CITADEL-204 study (NCT03144674, EudraCT 2017-000970-12) assessed efficacy an…
View article: Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society
Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society Open
Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening inflammatory syndrome. Lymphoma is the most common cause of HLH in adults. Previous studies have indicated poor patient outcomes in lymphoma-associated HLH. The recent…
View article: Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma
Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma Open
Introduction: Lactic acidosis is a medical emergency and in most cases results from an imbalance between tissue oxygenation and oxygen demand (Type A). However, Type B lactic acidosis occurs in the absence of a recognizable impairment in s…
View article: P11.67.B A RETROSPECTIVE STUDY OF 222 PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA - OUTCOMES INDICATIVE OF IMPROVED SURVIVAL OVER TIME
P11.67.B A RETROSPECTIVE STUDY OF 222 PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA - OUTCOMES INDICATIVE OF IMPROVED SURVIVAL OVER TIME Open
BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large retrospective studies on this rar…
View article: P1274: IMPACT OF AUTOLOGOUS TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL TRIPLETS: A SYSTEMATIC REVIEW AND META-ANALYSIS
P1274: IMPACT OF AUTOLOGOUS TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL TRIPLETS: A SYSTEMATIC REVIEW AND META-ANALYSIS Open
Topic: 22. Stem cell transplantation - Clinical Background: High-dose therapy with melphalan followed by autologous stem cell transplant at the upfront setting (upfront ASCT) has significantly improved clinical outcomes of myeloma patients…
View article: P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The rarity of PMLBCL has prevented the development of dedicated, powerful and validated prognostic systems. The International Prognostic Index (IPI) and its age-adjusted var…
View article: A RETROSPECTIVE STUDY OF 222 PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA—OUTCOMES INDICATIVE FOR IMPROVED SURVIVAL OVERTIME
A RETROSPECTIVE STUDY OF 222 PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA—OUTCOMES INDICATIVE FOR IMPROVED SURVIVAL OVERTIME Open
Introduction: Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large retrospective studies on this …
View article: REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS
REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS Open
Background: Real-life studies of moderate size have shown satisfactory but less impressive results compared with the original R-da-EPOCH publication for PMLBCL. However, large studies are needed efficacy and toxicity of R-da-EPOCH, the use…
View article: GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA Open
Introduction: Glofitamab (Glofit) is a bispecific CD20:CD3 antibody which redirects T cells to eliminate malignant B cells. The CD79b targeted antibody-drug conjugate polatuzumab vedotin (Pola) is approved in combination with bendamustine …
View article: Presence and activity of Fibrinogen like protein 2 in platelets
Presence and activity of Fibrinogen like protein 2 in platelets Open
Background Fibrinogen-like protein 2 (FGL2) is a serine protease capable of converting prothrombin into thrombin ( i . e ., prothrombinase-like activity) while bypassing the classic coagulation cascade. It has been reported to be expressed…
View article: <scp>CAR‐T</scp> cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and <scp>meta‐analysis</scp>
<span>CAR‐T</span> cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and <span>meta‐analysis</span> Open
We read with interest the letter by Luis Carlos Saiz and colleagues and thank you for the opportunity to discuss some of their comments. Saiz et al. raised concerns about analysing data which are still immature, especially data from an ong…
View article: The role of additional chemotherapy prior to autologous <scp>HCT</scp> in patients with relapse/refractory <scp>DLBCL</scp> in partial remission—A retrospective multicenter study
The role of additional chemotherapy prior to autologous <span>HCT</span> in patients with relapse/refractory <span>DLBCL</span> in partial remission—A retrospective multicenter study Open
Objectives To evaluate the role of additional chemotherapy before autologous hematopoietic cell transplantation (HCT) in patients with relapse/refractory diffuse large B‐cell lymphoma (DLBCL) who achieve partial remission following first s…
View article: Chimeric antigen receptor T‐cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis
Chimeric antigen receptor T‐cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis Open
Summary Treatment with high‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered standard of care (SOC) second‐line treatment for relapsed or refractory large B‐cell lymphoma (LBCL). However, outcomes rem…
View article: P1166: REPEAT BIOPSY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A NATIONWIDE SURVEY AND RETROSPECTIVE STUDY
P1166: REPEAT BIOPSY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A NATIONWIDE SURVEY AND RETROSPECTIVE STUDY Open
Background: Almost half of patients with diffuse large B-cell lymphoma (DLBCL) will have relapsed/refractory (R/R) disease after frontline immunochemotherapy. Although guidelines recommend histological confirmation of R/R disease, repeat b…
View article: P1203: THE OPTIMIZED HLH INFLAMMATORY (OHI) INDEX IDENTIFIES LYMPHOMA PATIENTS WITH UNEXPECTEDLY HIGH MORTALITY NOT RELATED TO DISEASE PROGRESSION
P1203: THE OPTIMIZED HLH INFLAMMATORY (OHI) INDEX IDENTIFIES LYMPHOMA PATIENTS WITH UNEXPECTEDLY HIGH MORTALITY NOT RELATED TO DISEASE PROGRESSION Open
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening inflammatory syndrome that may complicate hematologic malignancies (HM). We recently developed a simplified diagnostic and prognostic index termed the ‘optimized HL…
View article: P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES
P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES Open
Background: Real-life studies of moderate size have shown satisfactory but less impressive results compared with the initial study of R-da-EPOCH in PMLBCL. However, the strategies regarding the use of consolidative radiotherapy (RT) and th…